|
Delayed
OTC Markets
12:57:29 2026-05-28 pm EDT
|
5-day change | 1st Jan Change | ||
| 1.120 USD | -.--% |
|
-.--% | -22.76% |
| Sep. 10 | Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026. | CI |
| Aug. 17 | AB Science completes settlement and delivery of its private placement |  |
| Market Cap | 58.41M 67.41M 55.12M 50.01M 93.81M 6.46B 94.49M 658M 254M 3.28B 253M 248M 10.42B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 58.41M 67.41M 55.12M 50.01M 93.81M 6.46B 94.49M 658M 254M 3.28B 253M 248M 10.42B | EV / Sales 2026 * |
48.7x | EV / Sales 2027 * | 44.9x |
| Free-Float |
69.03% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: AB Science
| 6 months | -22.76% | ||
| Current year | -22.76% |
| Current year | 1.12 |  | 1.37 |
| 1 year | 1.12 | | 1.45 |
| 3 years | 0 | | 3.84 |
| 5 years | 0 | | 16.74 |
| 10 years | 0 | | 26.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2026-07-06 | |
Laurent Guy
DFI | Director of Finance/CFO | - | 2009-11-19 |
| Chief Tech/Sci/R&D Officer | - | 2018-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Alain Moussy
CHM | Chairman | - | 2001-07-10 |
Patrick Moussy
BRD | Director/Board Member | - | 2011-09-19 |
| Director/Board Member | 65 | 2021-06-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 67.79M | |
| +0.76% | -2.12% | +79.35% | +34.25% | 355B | |
| -0.68% | -3.37% | +22.35% | -20.78% | 66.33B | |
| +1.19% | +0.21% | +42.20% | +167.87% | 12.17B | |
| +1.55% | -7.41% | -9.13% | -17.39% | 7.47B | |
| -0.38% | -8.66% | -28.74% | -9.08% | 4.64B | |
| -0.38% | -2.83% | -33.92% | +12.39% | 4.42B | |
| +2.59% | -4.57% | -33.92% | -8.21% | 2.86B | |
| +2.03% | -0.20% | -3.74% | +44.62% | 2.42B | |
| +1.37% | -3.70% | -27.42% | -25.72% | 1.9B | |
| Average | +0.80% | -3.76% | +0.78% | +19.77% | 50.81B | |
| Weighted average by Cap. | +0.55% | -4.10% | +64.87% | +27.87% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.2M 1.38M 1.13M 1.03M 1.93M 133M 1.94M 13.52M 5.21M 67.34M 5.2M 5.09M 214M | 1.3M 1.5M 1.23M 1.11M 2.09M 144M 2.1M 14.65M 5.65M 72.95M 5.63M 5.51M 232M |
| Net income | - | - |
| Net Debt | - | - |
Employees
31
Sector
Pharmaceuticals
Calendar
Sep. 30
Earnings release - Q2 2026
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AB Stock
- ABSCF Stock
Select your edition
All financial news and data tailored to specific country editions
